{"groups":[{"description":"Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.\n\nvorinostat: Given PO\n\nrituximab: Given IV\n\nifosfamide: Given IV\n\ncarboplatin: Given IV\n\netoposide: Given IV\n\npharmacological study: Correlative studies\n\nlaboratory biomarker analysis: Correlative studies\n\ngene expression analysis: Correlative studies","id":"FG000","title":"Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"29"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"29"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}